-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Biological, CML, Diseases, Therapies, Biological Processes, immune cells, Cell Lineage, immunotherapy, Clinically relevant, Myeloid Malignancies, NK cells, immune mechanism, TKI
Sunday, December 6, 2020: 7:00 AM-3:30 PM
2144
Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Patrick Harrington, MRCP, FRCPath1,2*, Richard Dillon, MA, PhD, MRCP, FRCPath3,4, Deepti H. Radia, MRCPI, FRCPath2*, Donal P. McLornan, MRCP, PhD, FRCPath2*, Philippe Rousselot, MD PhD5*, Katayoun Rezvani, MD, PhD6, Shahram Kordasti, MD, PhD7, Claire Harrison, DM, FRCPath8 and Hugues de Lavallade, MD, PhD1,9*

1School of Cancer and Pharmaceutical Science, King's College London, London, United Kingdom
2Department of Clinical Haematology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
3Department of Medical and Molecular Genetics, King's College, London, United Kingdom
4Department of Clinical Haematology, Guy's & St Thomas' NHS Foundation Trust, London, ENG, United Kingdom
5Centre Hospitalier de Versailles, Le Chesnay, France
6Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
7Systems Cancer Immunology, Comprehensive Cancer Centre, King's College London, London, United Kingdom
8Department of Clinical Haematology, Guys and St Thomas NHS Trust, London, United Kingdom
9Department of Haematological Medicine, Kings College Hospital, NHS Foundation Trust, London, United Kingdom
2145
Dasatinib Promotes the Maturation of Healthy Donors and Chronic Myelogenous Leukemia Patients Derived Dendritic Cells

Wangjun Cao1*, Lin He2*, Hong Zheng, MD, PhD3, Xiaobing Huang4*, Xi Yang5*, Xiaodong WANG, MD6* and Jingying Dai, PhD4*

1School of Pharmacy, North Sichuan Medical College, Nanchong, China
2Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, China
3Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA
4Department of Hematology, Sichuan Provincial People's Hospital; Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, China
5Department of Hematology, Sichuan Provincial People’s Hospital, Affliated Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China
6Sichuan Provincial People’s Hospital, Affliated Hospital of University of Electronic Science and Technology of China, Chengdu, CHN
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>
*signifies non-member of ASH